Bortezomib, Ascorbic Acid, and Melphalan in Treating Patients With Newly Diagnosed Multiple Myeloma

Completed · Phase 2

Conditions studied: Multiple Myeloma and Plasma Cell Neoplasm

In brief

RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Ascorbic acid may help melphalan work better by making cancer cells more sensitive to the drug. Giving bortezomib together with ascorbic acid and melphalan may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving bortezomib together with ascorbic acid and melphalan works in treating patients with newly diagnosed multiple myeloma.

Key facts

Study ID

NCT00317811

Run by

Oncotherapeutics

People needed

35

Starts

2005-11-01

Last updated by the study team

2013-11-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Hematology-Oncology Medical Group of Fresno, Incorporated — Fresno, California, United States
• Hematology Oncology Medical Group of Orange County, Incorporated — Orange, California, United States
• Oncotherapeutics — West Hollywood, California, United States
• Florida Cancer Specialists - Bonita Springs — Bonita Springs, Florida, United States
• Florida Oncology Associates — Orange Park, Florida, United States
• Atlanta Cancer Care - Roswell — Roswell, Georgia, United States
• University of Chicago Cancer Research Center — Chicago, Illinois, United States
• SUNY Downstate Medical Center — Brooklyn, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.